-
-
-
-
-
-
-
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
-
-
-
-
-
-
-
Surface Oncology (SURF) PT Lowered to $14 at Wedbush, Following Earnings
-
-
-
-
-
-
-
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2020
-
-
-
-
-
-
-
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2019
-
-
-
-
-
-
-
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2018
-
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

